STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) today announces that the
company will present at the Erik Penser Bank Life Science Day,
Thursday December 2, 2021.
The presentation will be available after the meeting on
Medivirs website; www.medivir.com.
For additional information, please contact:
Magnus Christensen, interim CEO
and CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
About Medivir:
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
MIV-818, a pro-drug designed to selectively treat liver cancer
cells and to minimize side effects. Collaborations and
partnerships are important parts of Medivir's business model, and
the drug development is conducted either by Medivir or in
partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed
to IGM Biosciences (Nasdaq: IGMS) to be developed in combination
with IGM-antibodies for the treatment of solid tumors. Medivir's
share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap
list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-to-present-at-the-erik-penser-bank-life-science-day,c3463947
The following files are available for download:
|
https://mb.cision.com/Main/652/3463947/1503998.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-erik-penser-bank-life-science-day-301434763.html
SOURCE Medivir
